SAMI

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

SHIFTKEY AND ONSHIFT CONTINUE TO DRIVE IMPACT WITH SAMI ONE YEAR AFTER LAUNCH

Retrieved on: 
Wednesday, April 3, 2024
Workforce, Organization, SAMI, Empowerment, Human resources

DALLAS, April 3, 2024 /PRNewswire/ -- Last year, ShiftKey, a leading technology marketplace disrupting healthcare through data and workforce empowerment, and OnShift, a ShiftKey brand, launched their Schedule Automation Marketplace Integration (SAMI), a first-of-its-kind system that combines the full power of ShiftKey's workforce marketplace and OnShift's dashboard view and data. The result was empowering facilities with the resources and data-driven insights needed to make strategic workforce decisions in the short and long term.

Key Points: 
  • Over the past year, SAMI has grown to provide more than 600 healthcare organizations with a complete view of their schedule — giving total transparency and visibility into workforce planning.
  • These tools have helped organizations build a complete schedule proactively and cost-effectively, driving census growth that has generated more than $111M in annualized revenue for facilities (or customers) using SAMI.
  • SAMI users have also seen a remarkable reduction in agency hours by 45%, indicating a shift towards more efficient workforce planning practices.
  • Through its groundbreaking approach, with technologies such as SAMI, ShiftKey has revolutionized work by offering tools and technology to ensure better visibility into workforce needs.

Northern Trust Appointed by Sanlam Asset Management (Ireland) Limited

Retrieved on: 
Thursday, February 22, 2024
Banking, Asset Management, Professional Services, Finance, SAMI, Investment, Growth, Sanlam, Trust, NTRS, Northern Trust, FX, Financial services

Northern Trust (Nasdaq: NTRS) announces today that it is providing Sanlam Asset Management (Ireland) Limited (SAMI) with fund administration, transfer agency, custody, depositary and FX services.

Key Points: 
  • Northern Trust (Nasdaq: NTRS) announces today that it is providing Sanlam Asset Management (Ireland) Limited (SAMI) with fund administration, transfer agency, custody, depositary and FX services.
  • These funds are managed in conjunction with Sanlam’s London-based boutique asset management business, Sanlam Investments UK, its South African-based asset management business, Sanlam Investments and independent third-party managers.
  • Northern Trust is now serving as the single provider of asset servicing solutions for these funds.
  • The appointment builds upon an existing relationship between Sanlam Investments UK and Northern Trust as a client of its Integrated Trading Solutions outsourced trading desk.

OnShift Launches “OnShift Schedule X”

Retrieved on: 
Wednesday, September 27, 2023
Software, General Health, Health, Medical Devices, Data Management, Health Technology, Technology, Other Technology, Pressure, Growth, SAMI, Maintenance (technical)

OnShift , a ShiftKey company, today launched OnShift Schedule X , a modern scheduling technology that provides critical data and actionable insights to drive strategic workforce decisions at scale.

Key Points: 
  • OnShift , a ShiftKey company, today launched OnShift Schedule X , a modern scheduling technology that provides critical data and actionable insights to drive strategic workforce decisions at scale.
  • OnShift Schedule X propels facilities into the future by delivering the simplicity, flexibility and insights needed to drive success.
  • Key features include:
    Recurring schedule patterns that simplify schedule creation, saving time
    Our award-winning integrated solution, SAMI (Scheduling Automation Marketplace Integration), is ready for use with OnShift Schedule X.
  • For more information on OnShift Schedule X, or to schedule a demo, please visit: www.onshift.com/workforce-scheduling .

OKSI Set to Fly SAMI to Observe OSIRIS-REx Re-entry, Following Artemis I and SpaceX Missions

Retrieved on: 
Tuesday, August 22, 2023
Space Launch System, SAMI, Partnership, Langley Research Center, OSIRIS-REx, Bennu, Infrared, Utah Test and Training Range, Gulf Stream, United States Department of Defense, Asteroid, Spacecraft, Security, Mass spectral interpretation, Acquisition, MWIR, Planet, NASA, SLS, OSIRIS, Artemis, Observation, SpaceX, Air Warrior (U.S. Army), Starship, Filter, Communications satellite, Mars

OKSI is advancing the frontiers of space exploration, embarking on yet another collaboration with NASA & the SCIFLI team.

Key Points: 
  • OKSI is advancing the frontiers of space exploration, embarking on yet another collaboration with NASA & the SCIFLI team.
  • Previously, SAMI operated from a nose-mounted spherical gimbal on NASA's WB-57 aircraft to observe the Artemis I Moon Mission launch and SpaceX's Starship's first launch attempt.
  • Since the Artemis I and Starship missions, SAMI gained a UV-Visible imaging spectrometer to enhance its capabilities.
  • The integration of SAMI onto their Gulfstreams, along with tracking systems and optical-quality windows has opened doors to more flexible and responsive SAMI support for future NASA missions.

Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
International joint venture, Cras, De novo, Marketing, Public, Dialysis, Hemoperfusion, ESS, Medical University of South Carolina, Patient, Medical device, Intensive care unit, Software, University, Baxter, Research, MDSAP, Sepsis, Certification, UCSF, TSX, EDEN, FDA, SAMI, Observational study, COVID-19, PMX, Contract research organization, MUSC, Mortality, Breakthrough, Lipopolysaccharide, University of California, San Francisco, Clinical trial, Medical school, Septic shock, Joint venture, Infomed, ICU, Pharmaceutical industry, Silviculture, Nursing, Spectral

TORONTO, March 24, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Importantly, we are in the process of engaging a new Contract Research Organization (“CRO”) to oversee the Tigris trial.
  • The new company, i-Dialco, is exclusively focused on advancing commercialization of the SAMI and DIMI dialysis devices in the North American markets.
  • We anticipate our initiatives aimed at enhancing trial recruitment and enrollment will assist in completion of Tigris as expeditiously as possible.
  • With the establishment of i-Dialco, the previous Dialco operations were considered discontinued as at December 31, 2022.

ShiftKey & OnShift Launch Transformative System for Healthcare Facilities, the Schedule Automation Marketplace Integration “SAMI”

Retrieved on: 
Tuesday, March 21, 2023
Other Technology, Software, Human Resources, Networks, Internet, Consulting, Hardware, Hospitals, Electronic Design Automation, Data Management, Professional Services, Technology, Mobile, Wireless, Managed Care, Data Analytics, Health, Apps, Applications, Health Technology, Workforce, SAMI, Partnership, Patient, Management, Nursing

ShiftKey and OnShift today announced the launch of the Schedule Automation Marketplace Integration (SAMI), a first-of-its-kind system that combines the full power of ShiftKey’s workforce marketplace and OnShift’s dashboard view and data, empowering facilities with the resources and insights to make strategic workforce decisions in the short and long-term.

Key Points: 
  • ShiftKey and OnShift today announced the launch of the Schedule Automation Marketplace Integration (SAMI), a first-of-its-kind system that combines the full power of ShiftKey’s workforce marketplace and OnShift’s dashboard view and data, empowering facilities with the resources and insights to make strategic workforce decisions in the short and long-term.
  • “I’m thrilled to unveil SAMI in partnership with OnShift.
  • It’s a win for everyone.”
    The integration comes at no additional cost for facilities using the ShiftKey and OnShift platforms.
  • For more information on the SAMI product, or to schedule a demo, please visit: https://www.shiftkey.com/sami/ .

Arctech Meets with ACWA Power and China Energy Engineering Group

Retrieved on: 
Thursday, March 2, 2023
SAMI, CEEC, ACWA Power, Vision 2030, ACWA, Belt and Road Initiative, Belt, BIPV, Carbon, ASB, Management, Arctech Helsinki Shipyard, Road

KUNSHAN, China, March 2, 2023 /PRNewswire/ -- Arctech, the world's leading solar tracking, racking, and BIPV provider welcomed the senior management from ACWA Power and China Energy Engineering Group Co., Ltd. (hereafter "CEEC") at a business meeting in Arctech's headquarters, Kunshan, China.

Key Points: 
  • KUNSHAN, China, March 2, 2023 /PRNewswire/ -- Arctech, the world's leading solar tracking, racking, and BIPV provider welcomed the senior management from ACWA Power and China Energy Engineering Group Co., Ltd. (hereafter "CEEC") at a business meeting in Arctech's headquarters, Kunshan, China.
  • ACWA Power is the largest independent power and desalination water company in the Middle East, and CEEC is one of the largest comprehensive solutions providers for the power industry in the globe.
  • Cai Hao, President, and Chairman at Arctech extended a hearty welcome to Mohammad A. Abunayyan, Chairman of ACWA Power trip to China.
  • Mr. Cai said: "We have established a solid foundation for long-term cooperation among ACWA Power, CEEC, and Arctech, and aims at expediting carbon neutrality in the Middle East."

Arctech Meets with ACWA Power and China Energy Engineering Group

Retrieved on: 
Thursday, March 2, 2023
SAMI, CEEC, Multimedia, ACWA Power, Vision 2030, ACWA, Belt and Road Initiative, Belt, BIPV, Carbon, ASB, Oil, Arctech Helsinki Shipyard, Road

KUNSHAN, China, March 2, 2023 /PRNewswire/ -- Arctech, the world's leading solar tracking, racking, and BIPV provider welcomed the senior management from ACWA Power and China Energy Engineering Group Co., Ltd. (hereafter "CEEC") at a business meeting in Arctech's headquarters, Kunshan, China.

Key Points: 
  • KUNSHAN, China, March 2, 2023 /PRNewswire/ -- Arctech, the world's leading solar tracking, racking, and BIPV provider welcomed the senior management from ACWA Power and China Energy Engineering Group Co., Ltd. (hereafter "CEEC") at a business meeting in Arctech's headquarters, Kunshan, China.
  • ACWA Power is the largest independent power and desalination water company in the Middle East, and CEEC is one of the largest comprehensive solutions providers for the power industry in the globe.
  • Cai Hao, President, and Chairman at Arctech extended a hearty welcome to Mohammad A. Abunayyan, Chairman of ACWA Power trip to China.
  • Mr. Cai said: "We have established a solid foundation for long-term cooperation among ACWA Power, CEEC, and Arctech, and aims at expediting carbon neutrality in the Middle East."

Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments

Retrieved on: 
Thursday, January 12, 2023
Medical school, Hospital, PMX, Acute, Medical University of South Carolina, Hemoperfusion, Standard of care, Dialysis, EDEN, TSX, FDA, Total, Randomized controlled trial, Knowledge, Partnership, EAA, SAMI, Death, Marketing, Lipopolysaccharide, Patient, Sepsis, Observational study, Mortality, Clinical trial, Intensive care unit, Baxter, CDC, Septic shock, Pharmaceutical industry, Health insurance, Q4

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.

Key Points: 
  • The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.
  • Chris Seto, Chief Executive Officer of Spectral Medical, commented, “We continue to aggressively advance our Tigris trial with 50 of the 150 total patients now enrolled and randomized in the study.
  • Moreover, we have seen a 30-40% increase in sepsis cases at our trial sites compared to last summer.
  • To meet final trial enrollment in 2023, we estimate the need for approximately 20 productive trial sites.